133 related articles for article (PubMed ID: 20084971)
1. [Safety and immunogenicity of lyophilized live attenuated domestic varicella vaccine].
Chen EF; Jiang ZG; Li Q
Zhongguo Yi Miao He Mian Yi; 2009 Oct; 15(5):435-7. PubMed ID: 20084971
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of single dose live attenuated varicella vaccine (VR 795 Oka strain) in healthy Indian children: a randomized controlled study.
Mitra M; Faridi M; Ghosh A; Shah N; Shah R; Chaterjee S; Narang M; Bhattacharya N; Bhat G; Choudhury H; Kadhe G; Mane A; Roy S
Hum Vaccin Immunother; 2015; 11(2):443-9. PubMed ID: 25692656
[TBL] [Abstract][Full Text] [Related]
3. Long-term clinical studies of varicella vaccine at a regional hospital in Japan and proposal for a varicella vaccination program.
Ozaki T
Vaccine; 2013 Dec; 31(51):6155-60. PubMed ID: 24183712
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, safety and immunogenicity of live attenuated varicella vaccine in healthy children in China: double-blind, randomized, placebo-controlled clinical trial.
Hao B; Chen Z; Zeng G; Huang L; Luan C; Xie Z; Chen J; Bao M; Tian X; Xu B; Wang Y; Wu J; Xia S; Yuan L; Huang J
Clin Microbiol Infect; 2019 Aug; 25(8):1026-1031. PubMed ID: 30616012
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of a two-dose regime of varicella vaccine in children with cancers.
Leung TF; Li CK; Hung EC; Chan PK; Mo CW; Wong RP; Chik KW
Eur J Haematol; 2004 May; 72(5):353-7. PubMed ID: 15059071
[TBL] [Abstract][Full Text] [Related]
6. The immunogenicity and safety of live attenuated varicella-zoster virus vaccine in human immunodeficiency virus-infected children.
Taweesith W; Puthanakit T; Kowitdamrong E; Bunupuradah T; Wongngam W; Phasomsap C; Apornpong T; Bouko C; Pancharoen C
Pediatr Infect Dis J; 2011 Apr; 30(4):320-4. PubMed ID: 20975615
[TBL] [Abstract][Full Text] [Related]
7. [Study on epidemiological effect of the freeze-dried attenuated live varicella vaccine].
Ma FB; Luo LY; Zhang LH
Zhongguo Yi Miao He Mian Yi; 2009 Jun; 15(3):193-5. PubMed ID: 20084878
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of Bio Pox™, a live varicella vaccine (Oka strain) in Indian children: A comparative multicentric, randomized phase II/III clinical trial.
Dubey AP; Faridi MMA; Mitra M; Kaur IR; Dabas A; Choudhury J; Mukherjee M; Mishra D
Hum Vaccin Immunother; 2017 Sep; 13(9):2032-2037. PubMed ID: 28509605
[TBL] [Abstract][Full Text] [Related]
9. Safety and Immunogenicity of the Live Attenuated Varicella Vaccine in Vietnamese Children Aged 12 Months to 12 Years: An Open-Label, Single-Arm Bridging Study.
Hung PV; Giang LTH; Toi PL; Thuc VTM; Anh BDT; Pho DC; Hung PN
Viruses; 2024 May; 16(6):. PubMed ID: 38932134
[TBL] [Abstract][Full Text] [Related]
10. Safety of a second dose of varicella vaccine administered at 4 to 6 years of age in healthy children in Argentina.
Fridman D; Monti A; Bonnet MC; Armoni J; Stamboulian D
Hum Vaccin; 2011 Oct; 7(10):1066-71. PubMed ID: 21989288
[TBL] [Abstract][Full Text] [Related]
11. Immunization of HIV-infected children with varicella vaccine.
Levin MJ; Gershon AA; Weinberg A; Blanchard S; Nowak B; Palumbo P; Chan CY;
J Pediatr; 2001 Aug; 139(2):305-10. PubMed ID: 11487761
[TBL] [Abstract][Full Text] [Related]
12. Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4(+) T cells.
Levin MJ; Gershon AA; Weinberg A; Song LY; Fentin T; Nowak B;
J Infect Dis; 2006 Jul; 194(2):247-55. PubMed ID: 16779732
[TBL] [Abstract][Full Text] [Related]
13. [Investigation on sera prevalence rate of varicella and immunogenicity of varicella vaccine in healthy children].
Zhou T; Wang J; Qiu P
Zhonghua Liu Xing Bing Xue Za Zhi; 1998 Oct; 19(5):271-3. PubMed ID: 10322684
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and adverse effects of live attenuated varicella vaccine (Oka-strain) in children with chronic liver disease.
Nithichaiyo C; Chongsrisawat V; Hutagalung Y; Bock HL; Poovorawa Y
Asian Pac J Allergy Immunol; 2001 Jun; 19(2):101-5. PubMed ID: 11699716
[TBL] [Abstract][Full Text] [Related]
15. Reactogenicity and immunogenicity of a live-attenuated refrigerator-stable varicella vaccine (OKA strain) in healthy seronegative subjects age 10 months to 12 years.
Hadinegoro SR; Hindra IS; Han HH; Gatchalian S; Bock HL
Southeast Asian J Trop Med Public Health; 2009 Sep; 40(5):991-9. PubMed ID: 19842382
[TBL] [Abstract][Full Text] [Related]
16. Varicella vaccination: evidence for frequent reactivation of the vaccine strain in healthy children.
Krause PR; Klinman DM
Nat Med; 2000 Apr; 6(4):451-4. PubMed ID: 10742154
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of a live attenuated varicella vaccine in healthy Indian children aged 9-24 months.
Ramkissoon A; Coovadia HM; Jugnundan P; Haffejee IE; Meurice F; Vandevoorde D
S Afr Med J; 1995 Dec; 85(12):1295-8. PubMed ID: 8600589
[TBL] [Abstract][Full Text] [Related]
18. The safety profile of varicella vaccine: a 10-year review.
Galea SA; Sweet A; Beninger P; Steinberg SP; Larussa PS; Gershon AA; Sharrar RG
J Infect Dis; 2008 Mar; 197 Suppl 2():S165-9. PubMed ID: 18419392
[TBL] [Abstract][Full Text] [Related]
19. A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults.
Leroux-Roels I; Leroux-Roels G; Clement F; Vandepapelière P; Vassilev V; Ledent E; Heineman TC
J Infect Dis; 2012 Oct; 206(8):1280-90. PubMed ID: 22872734
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of Oka/Merck varicella vaccine in children vaccinated at 12-14 months of age versus 15-23 months of age.
Silber JL; Chan IS; Wang WW; Matthews H; Kuter BJ
Pediatr Infect Dis J; 2007 Jul; 26(7):572-6. PubMed ID: 17596796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
